Helicobacter Pylori Blood Biomarkers and Gastric Cancer Survival in China

Matthew G. Varga,Tianyi Wang,Hui Cai,Yong-Bing Xiang,Yu-Tang Gao,Bu-Tian Ji,Michael Pawlita,Tim Waterboer,Wei Zheng,Xiao-Ou Shu,Meira Epplein
DOI: https://doi.org/10.1158/1055-9965.epi-17-1084
2018-01-01
Abstract:Background: Infection with Helicobacter pylori is the leading risk factor for noncardia gastric cancer, yet its influence on prognosis of gastric cancer is largely unknown. Thus, exploring the role of Helicobacter pylori (H. pylori) in survival could lead to a greater understanding of the high mortality associated with gastric cancer. Methods: Seropositivity to 15 H. pylori antigens was assessed using a multiplex assay in two prospective cohorts, the Shanghai Men's Health Study and the Shanghai Women's Health Study. Multivariable-adjusted Cox proportional hazards regression was used to examine the association between prediagnostic H. pylori antigen levels and gastric cancer–specific survival. Results: Prediagnostic levels of H. pylori serum antibodies that were previously associated with gastric cancer incidence in this population were not associated with gastric cancer survival, whether assessed in a 6-antigen panel [HR = 1.29; 95% confidence interval (CI), 0.78–2.13 for men; HR = 0.93; 95% CI, 0.57–1.52 for women], focused on CagA+H. pylori (HR = 0.73; 95% CI, 0.44–1.20 forwomen; HR = 1.27; 95% CI, 0.70–2.31 for men) or on the high-risk biomarkers of dual Omp and HP 0305 seropositivity (HR = 0.97; 95% CI, 0.72–1.30 for women; HR = 1.37; 95% CI, 0.97–1.94 for men). Conclusions: Prediagnostic H. pylori antigen levels are not associated with gastric cancer survival in East Asian populations. Impact: Identification of additional factors associated with gastric cancer survival would further our understanding of the high mortality associated with this malignancy. Cancer Epidemiol Biomarkers Prev; 27(3); 342–4. ©2017 AACR.
What problem does this paper attempt to address?